FDA Inspection 1204858 — Sciegen Pharmaceuticals Inc
The FDA completed an inspection of Sciegen Pharmaceuticals Inc on April 21, 2023 in Hauppauge, NY. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). Product area: Drugs.
Inspection Details
- Classification
- Official Action Indicated (OAI) (OAI)
- End Date
- April 21, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Hauppauge, NY (United States)
Additional Details
Bioanalytical BA/BE